Immunogenic adverse events to CFTR modulators – An international survey
Journal of Cystic Fibrosis · 2025-05 · 24 (3) · 521-525
DOI: 10.1016/j.jcf.2025.03.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025-05. Verfasst von Ruth M Urbantat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Chloride Channel Agonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Berlin Institute of Health at Charité, Charité – Universitätsmedizin Berlin, European Cystic Fibrosis Society.
Themen: Patientensicherheit
Abstract (Originalsprache)
BACKGROUND: CFTR modulator therapy has unprecedented positive effects on people with CF (pwCF). However, immunogenic reactions to CFTR modulator therapy may lead to drug discontinuation. We aimed to identify pwCF, intolerant to CFTR modulator therapy due to suspected immunogenic adverse events (iAE). METHODS: This survey assessed the types of reaction (e.g. rash, liver injury, drug fever) including reactions after re-exposure and was completed by ECFS CTN Centers. RESULTS: Response rate to the survey was 74 %. 89 CF centers treating approximately 12000 to 17500 pwCF in 28 countries participated and 75 (84 %) CF centers reported discontinuation of CFTR modulator therapy. 37 (41.1 %) of CF centers reported iAE affecting 200 (1.1 - 1.7 %) pwCF. Detailed information about iAEs was provided for 41 of 200 (20.5 % of affected) pwCF. Of the iAEs reported in detail 33/41 (80.5 %) were associated with elexacaftor/tezacaftor/ivacaftor modulator therapy, 6 (14.6 %) with lumacaftor/ivacaftor and 2 (4.9 %) with tezacaftor/ivacaftor. 72 % of pwCF with iAE were re-exposed to CFTR modulator therapy. 32 % of re-exposed pwCF reported a second iAE. Rash and elevated liver enzymes were most frequently reported iAEs. CONCLUSIONS: iAE were mostly transient. Drug allergy to CFTR modulator therapy was rare, but highly relevant for individual pwCF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; German Center for Lung Research (DZL), Associated…
- University of Southampton Faculty of Medicine, School of Clinical and Experimental Sciences, Southampton SO17 1BJ, United Kingdom.
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
- Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool L69 3GE, United Kingdom.
- Respiratory Medicine, Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.
Förderung
- Berlin Institute of Health at Charité
- Charité – Universitätsmedizin Berlin
- European Cystic Fibrosis Society
- Chiesi Farmaceutici
- Medical Research Foundation
- Medical Research Council
Zitieren
APA
Urbantat, R. M., Behan, L., Wisniewski, S., Gardner, J., Stahl, M., Mall, M. A., Peckham, D., Naisbitt, D. J., & Roehmel, J. F. (2025). Immunogenic adverse events to CFTR modulators – An international survey. Journal of Cystic Fibrosis, 24(3), 521-525. https://doi.org/10.1016/j.jcf.2025.03.003
Vancouver
Urbantat RM, Behan L, Wisniewski S, Gardner J, Stahl M, Mall MA, et al. Immunogenic adverse events to CFTR modulators – An international survey. Journal of Cystic Fibrosis. 2025;24(3):521-525. doi:10.1016/j.jcf.2025.03.003
BibTeX
@article{Urbantat2025,
author = {Urbantat, Ruth M and Behan, Laura and Wisniewski, Sebastian and Gardner, Joshua and Stahl, Mirjam and Mall, Marcus A and Peckham, Daniel and Naisbitt, Dean J and Roehmel, Jobst F},
title = {Immunogenic adverse events to CFTR modulators – An international survey},
journal = {Journal of Cystic Fibrosis},
year = {2025},
volume = {24},
number = {3},
pages = {521--525},
doi = {10.1016/j.jcf.2025.03.003}
}
EUVIMED